Redeye iniates coverage of IDL Biotech
Redeye initiates coverage of IDL Biotech, aiming to transform the management of patients with bladder cancer and other life-threatening diseases through quicker and more cost-effective diagnosis. Past mis-steps in execution have hurt company’s credibility and at current EV of 100 MSEK, investors are failing to price any future growth. Read more and download the research update: http://bit.ly/2X0iEtk Start following companies at Redeye to receive the latest equity research within Life Science and